

**UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF MASSACHUSETTS**

**IN RE PHARMACEUTICAL INDUSTRY
AVERAGE WHOLESALE PRICE
LITIGATION**

**THIS DOCUMENT RELATES TO ALL
CLASS ACTIONS RELATING TO BMS
CLASS ACTION:**

MDL No. 1456

CIVIL ACTION: 01-CV-12257-PBS

Judge Patti B. Saris

**DECLARATION OF DANIEL COGGESHALL
REGARDING BMS SUPPLEMENTAL NOTICE**

The undersigned, Daniel Coggeshall, hereby states that:

1. I submit this Declaration in order to provide the Court and the parties to the above-captioned litigation with information regarding the mailing of the Supplemental Notices approved by the Court in its Order Directing Notice of Settlement Revision to Affected Class Members and Scheduling Fairness Hearing (the “Supplemental Notice Order”) dated May 24, 2011.
2. I am a Senior Project Administrator at Rust Consulting, Inc. (“Rust”) f/k/a Complete Claim Solutions. Pursuant to the Preliminary Approval Order, Rust was appointed as the Settlement Administrator. I am over 21 years of age and am not a party to this action. I have personal knowledge of the facts set forth herein, and if called as a witness, could and would testify competently hereto.
3. On May 26, 2011, pursuant to the Supplemental Notice Order, Rust mailed the Notice of Revision to Proposed Class Action Settlement Involving Certain Chemotherapy Drugs Sold by BMS (the “TPP Notice”) to 715 TPP Class members who had filed a claim form. A copy of the TPP Notice is attached hereto as Exhibit 1.

4. On May 26, 2011, pursuant to the Supplemental Notice Order, Rust mailed the Notice of Revision to Proposed Class Action Settlement Involving Certain Chemotherapy Drugs Sold by BMS (the “Consumer Notice”) to 3,922 Class 1 consumers who had filed a claim form and whose settlement amount calculated to less than the original settlement amount under the revised distribution formula. A copy of the Consumer Notice is attached hereto as Exhibit 2.

5. Counsel asked us to review the claims of the four objectors. They have been assigned claim numbers 5541, 11986, 13152 and 17292. Each of these objectors is receiving a lower amount under the revised distribution formula than under the original distribution formula because they each were administered Paraplatin and Taxol in periods during which no damage occurred under the damage calculations. Consequently, their prior recovery for these administrations was replaced by the \$50 flat payment per drug. Claimant No. 17292 also has eligible administrations of Taxol in 2002, which will receive double damages.

6. I declare under penalty of perjury that the foregoing is true and correct to the best of my knowledge.

Executed this 5th day of July, 2011 in Palm Beach Gardens, Florida.

/s/Daniel Coggeshall
Daniel Coggeshall

EXHIBIT 1

BMS AWP TPP SETTLEMENT ADMINISTRATOR
P.O. BOX 24648
WEST PALM BEACH, FL 33416

IMPORTANT LEGAL NOTICE
ATTENTION: PRESIDENT/CEO,
FUND ADMINISTRATOR OR LEGAL DEPARTMENT



* 0 1 2 3 4 5 6 7 8 9 *

<<NAME>>

<<ADDRESS>>

<<CITY>> <<ST>> <<ZIP>>

THIS PAGE IS FOR MAILING PURPOSES ONLY

THIS PAGE IS INTENTIONALLY LEFT BLANK

Authorized by the U.S. District Court for the District of Massachusetts

Notice of Revision to Proposed Class Action Settlement Involving Certain Chemotherapy Drugs Sold by BMS

1. What Is This Notice About?

There is a Proposed Settlement of a class action lawsuit involving Bristol-Myers Squibb (“BMS”) drugs Blenoxane®, Cytoxan®, Etopophos®, Paraplatin®, Rubex®, Taxol® and Vepesid® (referred to as the “BMS Drugs”). The name of the lawsuit is *In re: Pharmaceutical Industry Average Wholesale Price Litigation*, Docket No. 01-CV-12257-PBS, MDL No. 1456.

You were mailed this Notice because you previously filed a Claim Form in response to an earlier Notice that was sent to you. On the Claim Form, you indicated that you made a payment from January 1, 1991 through December 31, 2004 for a BMS Drug.

This revised Notice informs you of a change in the terms of the Proposed Settlement.

2. What Is The Relevant Change In The Terms Of The Proposed Settlement?

Under the Proposed Settlement, BMS will pay \$19 million to settle the lawsuit. This amount is meant to satisfy the claims of both Third-Party Payors (“TPPs”) who meet the criteria for inclusion in one of the two Settlement Classes as well as claims by consumers who made percentage co-payments and full cash payments based on the published Average Wholesale Price (“AWP”). All costs associated with notice and administration, attorneys’ fees and litigation costs, and compensation to the named class representatives for time spent providing documents and testimony in connection with this case will be paid from the \$19 million settlement amount, except that BMS will pay 50% of the costs of notice up to \$1 million.

Under the initial proposal, 77% (or \$14,630,000) of the gross settlement amount was designated to satisfy the claims of TPPs. The remaining 23% (or \$4,370,000) of the gross settlement amount was designated for the purpose of paying consumer claims. Consumers and TPPs are sharing the costs of notice and administration equally.

The Court considered the Proposed Settlement at a hearing held March 28, 2011. Among other things, the Court requested that the Proposed Settlement be modified to provide more money to consumer members of the Classes. Afterward, a mediation was held between Allocation Counsel for consumers and TPPs, which produced an Agreement that provided Consumers with an additional \$1,000,000. Thus, the Agreement now provides that consumers will receive a gross settlement amount of \$5,370,000 (28%), and that TPPs will receive a gross settlement amount of \$13,630,000 (72%).

All other terms of the Proposed Settlement relevant to TPPs remain unchanged. Other changes relating to the distribution methodology apply only to consumers.

The Court has approved the Proposed Settlement, as revised, on a preliminary basis. It has further determined that the revision does not warrant a second “opt out” period in which class members who declined to exclude themselves before should now be offered another chance to do so. Accordingly, if the Proposed Settlement is finally approved as revised, you will be bound by its terms. The Court will hold a Hearing to decide whether the revised Proposed Settlement should be finally approved (*See Question 4*).

**3. May I Object To, Or Comment On, The Revision To
The Proposed Settlement?**

Yes. If you have comments about, or disagree with, any aspect of the revision to the Proposed Settlement, you may express your views to the Court. You must do this in writing. Your written response must include:

- Your name, address, telephone number, a brief explanation of your reasons for objection, and
- The case number (Civil Action Number: 01-CV-12257-PBS, MDL No. 1456).

*Your legal rights are affected even if you do not act.
Read this Notice carefully.*

The document **must** be signed to ensure the Court's review. The response must be filed with the Court at the following address on or before **July 1, 2011**: Clerk of Court, John Joseph Moakley U.S. Courthouse, 1 Courthouse Way, Suite 2300, Boston, Massachusetts 02210 and served on Counsel for the Parties so that the objection is received on or before **July 1, 2011** at the following addresses:

Counsel for the Class

Steve W. Berman
Hagens Berman Sobol Shapiro LLP
1918 Eighth Avenue, Suite 3300
Seattle, WA 98101

Counsel for BMS

Lyndon M. Tretter
Hogan Lovells US LLP
875 Third Avenue
New York, NY 10022

In addition, your document must clearly state that it relates to the "BMS Settlement." If you file or present an objection, you will be subject to the jurisdiction of the Court.

4. When And Where Will The Court Decide On Whether To Grant Final Approval Of The Proposed Settlement?

The Court will hold a Hearing on July 7, 2011 at 9:30 a.m., to consider whether it is fair, reasonable and adequate. At the Hearing, the Court will also consider whether to approve the Proposed Settlement; the request for attorneys' fees and expenses; and any comments or objections. You are not required to attend, but may do so at your own expense.

If you want your own lawyer instead of Class Counsel to speak at the Final Approval Hearing, you must give the Court a paper that is called a "Notice of Appearance." The Notice of Appearance must include:

- Your name, address, telephone number, signature;
- The name, and number of the lawsuit (Civil Action Number: 01-CV-12257-PBS, MDL No. 1456);
- State that you wish to enter an appearance at the Final Approval Hearing; and
- Any documentation in support of such opposition.

Your Notice of Appearance **must** be filed with the Court on or before **July 1, 2011** and served on Counsel so that it is received on or before **July 1, 2011**. The Notice of Appearance must be filed with the Court and served on Counsel at the addresses set forth above in response to Question 3.

5. Where Do I Obtain More Information?

You may obtain more information, including a copy of the original Notice that was previously mailed to you, by visiting the BMS AWP Settlement web site at www.BMSAWPSettlement.com, by calling 1-877-690-7097, or by writing to:

BMS AWP TPP Settlement Administrator
P.O. Box 24648
West Palm Beach, FL 33416

DATED: May 26, 2011

BY ORDER OF THE COURT

EXHIBIT 2

BMS AWP CLASS 1 SETTLEMENT ADMINISTRATOR
P.O. BOX 2364
FARIBAULT, MN 55021-9064

IMPORTANT LEGAL NOTICE



* 0 1 2 3 4 5 6 7 8 9 *

<<NAME>>

<<ADDRESS>>

<<CITY>> <<ST>> <<ZIP>>

THIS PAGE IS FOR MAILING PURPOSES ONLY

THIS PAGE IS INTENTIONALLY LEFT BLANK

Authorized by the U.S. District Court for the District of Massachusetts

Notice of Revision to Proposed Class Action Settlement Involving Certain Chemotherapy Drugs Sold by BMS**1. What Is This Notice About?**

There is a Proposed Settlement of a class action lawsuit involving Bristol-Myers Squibb ("BMS") drugs Blenoxane®, Cytoxan®, Etopophos®, Paraplatin®, Rubex®, Taxol® and Vepesid® (referred to as the "BMS Drugs"). The name of the lawsuit is *In re: Pharmaceutical Industry Average Wholesale Price Litigation*, Docket No. 01-CV-12257-PBS, MDL No. 1456.

You were mailed this Notice because you previously returned a Claim Card in response to an earlier Notice that was sent to you. On the Claim Card, you indicated that you made a percentage co-payment from January 1, 1991 through December 31, 2004 for a BMS Drug under Medicare Part B.

This revised Notice informs you of changes in the terms of the Proposed Settlement. In sum, the amount of money allocated to Consumers has been increased, and the proposed distribution has been altered to more closely track estimated damages for each individual BMS Drug. You are receiving this Notice because our records indicate that your total compensation across all settled BMS Drugs will be reduced under the Proposed Settlement as revised.

2. What Are The Changes In The Terms Of The Proposed Settlement?

The Court considered the Proposed Settlement at a hearing held March 28, 2011. The Court requested that the Proposed Settlement be modified to provide more money to Consumers and to base the distribution among the various Consumers more closely on estimated damages for each individual BMS Drug. Plaintiffs subsequently presented a revision to the Court, which the Court approved on a preliminary basis.

The total amount of money available to pay Consumer claims, including those Consumers who participated in Medicare Part B and those who made a percentage co-payment or cash payment for BMS Drugs outside of the Medicare Part B program, has been **increased** from \$4,370,000 to \$5,370,000.

And the manner in which your payment will be calculated has changed. Under the previous formula, the Claims Administrator would calculate your "Total Recognized Claim" by adding two amounts:

- Payment obligations for Cytoxan®, Taxol® and Vepesid® from January 1, 1991 through December 31, 2004 multiplied by a factor of three (3x); and
- Payment obligations for Blenoxane®, Etopophos®, Paraplatin®, Rubex® inside this time period (with no multiplication factor).

Your Total Recognized Claim will now be calculated differently. It will be based on the Court's findings from a prior trial against BMS in this same litigation and Plaintiffs' expert's calculation of estimated overcharges associated with the alleged price inflation for the BMS Drugs.

Your Total Recognized Claim will now be determined according to a three step process:

1. For the drugs Cytoxan®, Taxol® and Vepesid®, the Claims Administrator will apply the expert's estimated overcharge percentage for all administrations during the following years (years not indicated receive \$0):

Cytoxan®: 1991-2004 Taxol®: 2002-2003 Vepesid®: 1993-1999, 2001-2004

2. The amounts determined in Step 1 will be doubled for the following drugs and years for which the Court found liability in the prior trial: Cytoxan®, 1998-2002; Taxol®, 2002; and Vepesid®, 1998-1999, 2001-2002.
3. In Step 3, a \$50 payment will be allocated for all administrations of each of the following drugs: Blenoxane®, Etopophos®, Paraplatin®, Rubex®. In addition, all Taxol® administrations during the years 1991-2001 will also be allocated \$50. The foregoing payments are a flat \$50 per drug, without regard to how many administrations you received of the particular drug. For the foregoing drugs (and the time period indicated for Taxol®), either the Court found no liability at the prior trial, or Plaintiffs' expert determined that there were no or very minimal alleged overcharges.

The sum of these figures will be your Total Recognized Claim. For those claimants whose Total Recognized Claim sums to less than \$50, the distribution formula steps them up to \$50, so that \$50 becomes the minimum Total Recognized Claim for eligible claimants.

*Your legal rights are affected even if you do not act.
Read this Notice carefully.*

If there is enough money based on the number of claims received, your payment will be 100% of your Total Recognized Claim. If there is not enough money to pay all Consumers 100% of their Total Recognized Claims, each consumer's claim will be reduced proportionately.

If you are eligible to receive a payment, the net result of these changes to the Proposed Settlement is that your payment will be lower than under the initial distribution formula.

The remaining terms of the Proposed Settlement remain unchanged. The Court has determined that the above revision does not warrant a second "opt out" period in which class members who declined to exclude themselves before should now be offered another chance to do so. Accordingly, if the Proposed Settlement is finally approved as revised, you will be bound by its terms.

3. May I Object To, Or Comment On, The Revision To The Proposed Settlement?

Yes. If you have comments about, or disagree with, any aspect of the revision to the Proposed Settlement, you may express your views to the Court. You must do this in writing. Your written response must include:

- Your name, address, telephone number, a brief explanation of your reasons for objection, and
- The case number (Civil Action Number: 01-CV-12257-PBS, MDL No. 1456).

The document **must** be signed to ensure the Court's review. The response must be filed with the Court at the following address on or before **July 1, 2011**: Clerk of Court, John Joseph Moakley U.S. Courthouse, 1 Courthouse Way, Suite 2300, Boston, Massachusetts 02210 and served on Counsel for the Parties so that the objection is **received** on or before **July 1, 2011** at the following addresses:

Counsel for the Class

Steve W. Berman
Hagens Berman Sobol Shapiro LLP
1918 Eighth Avenue, Suite 3300
Seattle, WA 98101

Counsel for BMS

Lyndon M. Tretter
Hogan Lovells US LLP
875 Third Avenue
New York, NY 10022

In addition, your document must clearly state that it relates to the "BMS Settlement." If you file or present an objection, you will be subject to the jurisdiction of the Court.

4. When And Where Will The Court Decide On Whether To Grant Final Approval Of The Proposed Settlement?

The Court will hold a Hearing on July 7, 2011 at 9:30 a.m., to consider whether it is fair, reasonable and adequate. At the Hearing, the Court will also consider whether to approve the Proposed Settlement; the request for attorneys' fees and expenses; and any comments or objections. You are not required to attend, but may do so at your own expense.

If you want your own lawyer instead of Class Counsel to speak at the Final Approval Hearing, you must give the Court a paper that is called a "Notice of Appearance." The Notice of Appearance must include:

- Your name, address, telephone number, signature;
- The name, and number of the lawsuit (Civil Action Number: 01-CV-12257-PBS, MDL No. 1456);
- State that you wish to enter an appearance at the Final Approval Hearing; and
- Any documentation in support of such opposition.

Your Notice of Appearance **must** be filed with the Court on or before **July 1, 2011** and served on Counsel so that it is **received** on or before **July 1, 2011**. You cannot speak at the Hearing if you previously asked to be excluded from the Proposed Settlement Class. The Notice of Appearance must be filed with the Court and served on Counsel at the addresses set forth above in response to Question 3.

5. Where Do I Obtain More Information?

You may obtain more information, including a copy of the original Notice that was previously mailed to you, by visiting the BMS AWP Settlement web site at www.BMSAWPSettlement.com, by calling 1-877-690-7097, or by writing to:

BMS AWP Class1 Settlement Administrator
P.O. Box 2364
Faribault, MN 55021-9064

CERTIFICATE OF SERVICE

I hereby certify that I, Steve W. Berman, an attorney, caused a true and correct copy of the foregoing, ***Declaration of Daniel Coggeshall Regarding BMS Supplemental Notice***, to be delivered to all counsel of record by electronic service pursuant to Paragraph 11 of the Case Management Order No. 2, by sending on July 5, 2011, a copy to LEXISNexis File & Serve for posting and notification to all parties.

/s/ Steve W. Berman

Steve W. Berman